The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://majarjhv208512.plpwiki.com/7327644/glp_3_retatrutide_a_comparative_analysis